Supriya Lifescience Fair Value
Supriya Lifescience fair value. Supriya Lifescience (SUPRIYA) average fair value is ₹949.97 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹899.55 (+5.61%), fair value range ₹401.21–₹2182.61. Explore SUPRIYA true value to estimate fundamental worth using multiple valuation models.
Fair Value Analysis Export
SUPRIYA Fair Value vs Current Price — Valuation Summary
SUPRIYA average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Check SUPRIYA company valuation to track the company's total market size over time.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
SUPRIYA Fair Value Analysis — Data Sources & Coverage
Supriya Lifescience financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Supriya Lifescience share price chart.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
SUPRIYA vs Healthcare Sector Peers — P/E, P/B & Market Cap
Supriya Lifescience P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.